These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35902432)

  • 1. Escalating de-escalation in breast cancer treatment.
    Sacchini V; Norton L
    Breast Cancer Res Treat; 2022 Sep; 195(2):85-90. PubMed ID: 35902432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-Escalating the Management of In Situ and Invasive Breast Cancer.
    Angarita FA; Brumer R; Castelo M; Esnaola NF; Edge SB; Takabe K
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.
    McGee SF; Clemons M; Savard MF
    Curr Oncol; 2022 Jun; 29(6):4125-4137. PubMed ID: 35735438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Heil J; Kuerer HM; Pfob A; Rauch G; Sinn HP; Golatta M; Liefers GJ; Vrancken Peeters MJ
    Ann Oncol; 2020 Jan; 31(1):61-71. PubMed ID: 31912797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
    See SHC; Siziopikou KP
    Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
    Leon-Ferre RA; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
    Esgueva A; Siso C; Espinosa-Bravo M; Sobrido C; Miranda I; Salazar JP; Rubio IT
    J Surg Oncol; 2021 Jan; 123(1):71-79. PubMed ID: 33002230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalating and escalating surgery in the management of early breast cancer.
    Morrow M
    Breast; 2017 Aug; 34 Suppl 1():S1-S4. PubMed ID: 28673537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient perspectives on chemotherapy de-escalation in breast cancer.
    Rocque GB; Williams CP; Andrews C; Childers TC; Wiseman KD; Gallagher K; Tung N; Balch A; Lawhon VM; Ingram SA; Brown T; Kaufmann T; Smith ML; DeMichele A; Wolff AC; Wagner L
    Cancer Med; 2021 May; 10(10):3288-3298. PubMed ID: 33932097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
    Prakash I; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Fayanju OM
    Breast Cancer Res Treat; 2021 Apr; 186(2):535-550. PubMed ID: 33206290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for positive margins in conservative surgery for breast cancer after neoadjuvant chemotherapy.
    Bouzón A; Acea B; García A; Iglesias Á; Mosquera J; Santiago P; Seoane T
    Cir Esp; 2016; 94(7):379-84. PubMed ID: 27158077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives.
    Sabatino V; Pignata A; Valentini M; Fantò C; Leonardi I; Campora M
    Cancer Treat Res; 2023; 188():105-147. PubMed ID: 38175344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ibrahim MF; Mazzarello S; Shorr R; Vandermeer L; Jacobs C; Hilton J; Hutton B; Clemons M
    Ann Oncol; 2015 Nov; 26(11):2205-13. PubMed ID: 26122727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.